Large scale profiling of signalling pathways reveals an asthma specific signature in bronchial smooth muscle cells
Background Bronchial smooth muscle (BSM) cells from asthmatic patients maintain in vitro a distinct hyper reactive "primed" phenotype, characterized by increased release of pro inflammatory factors and mediators, as well as hyperplasia and/or hypertrophy. This "primed" phenotype helps to understand pathogenesis of asthma, as changes in BSM function are essential for manifestation of allergic and inflammatory responses and airway wall remodelling. Objective To identify signalling pathways in cultured primary BSMs of asthma patients and non asthmatic subjects by genome wide profiling of differentially expressed mRNAs and activated intracellular signalling pathways (ISPs) Methods Transcriptome profiling by cap analysis of gene expression (CAGE) which permits selection of preferentially capped mRNAs most likely to be translated into proteins, was performed in human BSM cells from asthmatic (n=8) and non asthmatic (n=6) subjects and OncoFinder tool were then exploited for identification of ISP deregulations. Results CAGE revealed >600 RNAs differentially expressed in asthma vs control cells (p<=0.005) with asthma samples showing a high degree of similarity among them. Comprehensive ISP activation analysis revealed that among 269 pathways analysed, 145 (p<0.05) or 103 (p<0.01) are differentially active in asthma, with profiles that clearly characterize BSM cells of asthmatic individuals. Notably, we identified 7 clusters of coherently acting pathways functionally related to the disease, with ISPs down regulated in asthma mostly targeting cell death promoting pathways and up regulated ones affecting cell growth and proliferation, inflammatory response, control of smooth muscle contraction and hypoxia related signalization. Conclusions These first time results can now be exploited toward development of novel therapeutic strategies targeting ISP signatures linked to asthma pathophysiology.
Oncotarget